EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials

Anja C L Mortensen, Tabassom Mohajershojai, Amanda Gustafsson, Hanna Berglund, Ram Kumar Selvaraju, Camilla Hofström, Helena Persson, Mats Ohlin, Thuy A Tran, Anton Forsberg Morén, Piotr Ochniewicz, Jan Zedenius und 3 weitere

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.270782 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Anja C L Mortensen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; anja.lundgren.mortensen@ki.se. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Lutetium, Radioisotopes, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted radionuclide therapy is an emerging potent therapeutic strategy in oncology. The cell surface antigen CD44v6 is a potential pan-cancer target for radionuclide therapy. This study aimed to evaluate the therapeutic efficacy, biodistribution, dosimetry, and safety profile of AKIR001, an antibody targeting CD44v6 labeled with 177Lu.

Methods

The biodistribution and preclinical dosimetry of [177Lu]Lu-AKIR001 were calculated in the highly CD44v6-expressing A431 murine xenograft model, with subsequent extrapolation to predict human dosimetry. Therapeutic efficacy was evaluated across 3 xenograft models, 2 with high and 1 with moderate levels of CD44v6, using multiple dosing levels, fractionation regimens, and combinations with cisplatin. Preclinical toxicology was evaluated in a cross-reactive rabbit model and complemented by a PET imaging study using 68Ga-labeled AKIR001 in a cynomolgus macaque.

Results

Biodistribution studies confirmed the high and selective tumor uptake of [177Lu]Lu-AKIR001, resulting in favorable dosimetry predictions for clinical application. Therapeutic evaluations demonstrated significant dose-dependent efficacy in all tested xenograft models, with fractionated dosing (2 doses) resulting in complete tumor regression in 80% of the animals in a radioresistant xenograft model. Biodistribution in rabbits demonstrated low uptake in normal tissues, and a good-laboratory-practice study using an excessive dose of AKIR001 was well tolerated, with no signs of adverse effects. PET imaging in a cynomolgus macaque corroborated these findings.

Conclusion

Collectively, these data strongly support the therapeutic efficacy, safety, and dosimetry of [177Lu]Lu-AKIR001, justifying its advancement into clinical trials. A phase 1 clinical trial of [177Lu]Lu-AKIR001for CD44v6-positive solid cancers (NCT06639191) is currently recruiting patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsLutetiumRadioisotopesAntibodies, MonoclonalAnimalsHumansMiceRabbitsCell Line, TumorTissue DistributionFemaleRadiometryMacaca fascicularisXenograft Model Antitumor AssaysRadiopharmaceuticalsPositron-Emission Tomography

Stichwörter der Autor:innen

CD44v6RPTrADCsradioantibody–drug conjugatestranslational oncology

Substanzen

Hyaluronan ReceptorsLutetiumLutetium-177CD44v6 antigenRadioisotopesAntibodies, MonoclonalRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; anja.lundgren.mortensen@ki.se.
  • Department of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
  • Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Preclinical PET-MRI Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  • Drug Discovery and Development, Science for Life Laboratories and Royal Institute of Technology, Stockholm, Sweden.
  • Drug Discovery and Development, Science for Life Laboratories and Department of Immunotechnology, Lund University, Lund, Sweden.

Zitieren

APA

Mortensen, A. C. L., Mohajershojai, T., Gustafsson, A., Berglund, H., Selvaraju, R. K., Hofström, C., Persson, H., Ohlin, M., Tran, T. A., Morén, A. F., Ochniewicz, P., Zedenius, J., Bernhardt, P., Frejd, F. Y., & Nestor, M. (2026). Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270782

Vancouver

Mortensen ACL, Mohajershojai T, Gustafsson A, Berglund H, Selvaraju RK, Hofström C, et al. Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270782

BibTeX
@article{Mortensen2026,
  author = {Mortensen, Anja C L and Mohajershojai, Tabassom and Gustafsson, Amanda and Berglund, Hanna and Selvaraju, Ram Kumar and Hofström, Camilla and Persson, Helena and Ohlin, Mats and Tran, Thuy A and Morén, Anton Forsberg and Ochniewicz, Piotr and Zedenius, Jan and Bernhardt, Peter and Frejd, Fredrik Y and Nestor, Marika},
  title = {Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.270782}
}
Kostenlos starten →